DexCom (DXCM) PT Lowered to $140.00 at UBS Group

DexCom (NASDAQ:DXCM) had its target price decreased by UBS Group from $150.00 to $140.00 in a research note released on Tuesday, BenzingaRatingsTable reports. UBS Group currently has a neutral rating on the medical device company’s stock.

DXCM has been the subject of several other research reports. Cowen boosted their price objective on DexCom from $150.00 to $175.00 and gave the company an outperform rating in a report on Friday, February 22nd. Morgan Stanley upped their price target on DexCom from $135.00 to $160.00 and gave the stock an equal weight rating in a research note on Monday, February 25th. Canaccord Genuity upped their price target on DexCom from $140.00 to $160.00 and gave the stock a buy rating in a research note on Friday, February 22nd. ValuEngine cut DexCom from a strong-buy rating to a buy rating in a research note on Monday, April 1st. Finally, Piper Jaffray Companies raised their price target on DexCom to $165.00 and gave the company an overweight rating in a research note on Wednesday, January 9th. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $152.31.

Shares of DXCM stock traded up $2.58 on Tuesday, reaching $122.95. 1,513,890 shares of the company’s stock were exchanged, compared to its average volume of 1,372,661. The company has a debt-to-equity ratio of 1.52, a quick ratio of 7.32 and a current ratio of 7.64. The firm has a market capitalization of $11.19 billion, a P/E ratio of 409.83 and a beta of 0.73. DexCom has a 52 week low of $80.09 and a 52 week high of $156.16.

DexCom (NASDAQ:DXCM) last issued its earnings results on Wednesday, May 1st. The medical device company reported ($0.05) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.12. The business had revenue of $280.50 million during the quarter, compared to analyst estimates of $246.10 million. DexCom had a positive return on equity of 4.98% and a negative net margin of 12.32%. DexCom’s revenue was up 52.1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.30) EPS. As a group, sell-side analysts forecast that DexCom will post 0.46 EPS for the current year.

In related news, Director Mark G. Foletta sold 1,000 shares of the firm’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $150.28, for a total value of $150,280.00. Following the transaction, the director now directly owns 4,052 shares in the company, valued at approximately $608,934.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Steven Robert Pacelli sold 3,596 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $116.61, for a total transaction of $419,329.56. The disclosure for this sale can be found here. Insiders sold a total of 96,530 shares of company stock worth $13,467,422 over the last quarter. 1.80% of the stock is currently owned by company insiders.

Institutional investors have recently modified their holdings of the business. Laurel Wealth Advisors LLC bought a new stake in DexCom in the 4th quarter valued at $26,000. Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of DexCom during the 4th quarter worth about $33,000. Canton Hathaway LLC bought a new position in shares of DexCom during the 1st quarter worth about $41,000. First Hawaiian Bank lifted its holdings in shares of DexCom by 75.6% during the 4th quarter. First Hawaiian Bank now owns 395 shares of the medical device company’s stock worth $47,000 after acquiring an additional 170 shares during the period. Finally, Bremer Trust National Association bought a new position in shares of DexCom during the 4th quarter worth about $49,000. 96.88% of the stock is owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Article: Why do earnings reports matter?

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.